COPD treatment
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
"pulmonary disease, chronic obstructive"[MeSH Terms] AND treatment
Searching the Web
GOLD 2026 COPD pocket guide pharmacological treatment exacerbation official
Reading File
Reading File
Reading Web Page
https://goldcopd.org/wp-content/uploads/2026/01/GOLD-Pocket-…
COPD treatment
COPD care aims to reduce breathlessness, prevent exacerbations, improve exercise tolerance, and slow further lung damage. Treatment should be based on confirmed spirometry, symptoms, exacerbation history, blood eosinophils, comorbidities, and inhaler technique.
1. Measures for everyone
- Stop smoking or vaping. This is the most effective intervention to slow decline in lung function.
- Avoid occupational dust, biomass smoke, and air pollution where possible.
- Vaccination: influenza, COVID-19, pneumococcal, and age-appropriate RSV, shingles, and Tdap vaccines.
- Teach and recheck inhaler technique and adherence at every review.
- Regular exercise, nutrition support if needed, and pulmonary rehabilitation, especially if breathless or after a hospitalization.
- Treat comorbid conditions such as heart failure, anxiety/depression, osteoporosis, sleep apnea, and malnutrition.
2. Stable COPD inhalers
| Clinical situation | Usual treatment approach |
|---|---|
| Occasional breathlessness | A bronchodilator, preferably a long-acting inhaler if symptoms are more than very occasional |
| Persistent symptoms / exercise limitation | LABA + LAMA dual bronchodilator |
| Frequent or significant exacerbations | LABA + LAMA; consider adding inhaled corticosteroid (ICS) in selected patients |
| Frequent exacerbations plus eosinophils ≥300 cells/µL | Consider initial triple therapy: LABA + LAMA + ICS |
| Still exacerbating on LABA + LAMA | Add ICS particularly if eosinophils ≥100 cells/µL; benefit is more likely as the eosinophil count rises |
- SABA: short-acting beta-agonist, for example salbutamol/albuterol, used as a quick-relief inhaler.
- SAMA: short-acting muscarinic antagonist, for example ipratropium.
- LABA: long-acting beta-agonist, for example formoterol, salmeterol.
- LAMA: long-acting muscarinic antagonist, for example tiotropium, umeclidinium.
- ICS: inhaled corticosteroid, for example budesonide or fluticasone.
Current GOLD guidance favors LABA + LAMA as initial treatment for symptomatic patients and for patients at higher exacerbation risk; ICS is not used routinely for all COPD patients. It is most useful where exacerbations persist and blood eosinophils suggest likely steroid responsiveness. GOLD 2026 report
Important: ICS can increase pneumonia risk, so it should be reviewed if pneumonia or significant adverse effects occur. If the patient also has asthma, treatment should follow asthma principles and include ICS.
Bronchodilators are the central therapy. Short-acting beta-agonist and/or ipratropium relieve acute symptoms; persistent dyspnea generally calls for a LABA, LAMA, or both. - Katzung's Basic and Clinical Pharmacology, 16th ed., p. 565
3. Additional options for selected patients
- Roflumilast: may reduce exacerbations in severe COPD with chronic bronchitis and low FEV1, particularly after prior hospitalization. Common problems include nausea, diarrhea, weight loss, insomnia, and mood effects.
- Azithromycin prevention therapy: sometimes considered for recurrent exacerbations, especially in former smokers, after checking hearing, QT-risk, resistance concerns, and specialist advice.
- Mucolytics: may help selected people with chronic sputum production.
- Avoid routine long-term oral steroids due to major toxicity.
- Theophylline/methylxanthines are generally avoided because benefit is limited and adverse effects/interactions are substantial.
4. Treating an acute COPD exacerbation
An exacerbation means a sudden worsening of breathlessness, cough, or sputum beyond usual day-to-day variation.
Typical management:
- Increase short-acting bronchodilator: SABA, with or without ipratropium.
- Short course of oral corticosteroid for moderate or severe attacks, usually no more than 5 days.
- Antibiotics for about 5 days when sputum becomes purulent, bacterial infection is likely, or ventilatory support is required.
- Give controlled oxygen if hypoxemic and assess for pneumonia, pulmonary embolism, heart failure, pneumothorax, or arrhythmia.
- Noninvasive ventilation is indicated when acute hypercapnic respiratory failure or significant work of breathing develops.
GOLD recommends short-acting bronchodilators first, systemic steroids for up to 5 days in moderate/severe exacerbations, and antibiotics in appropriate patients with purulent sputum or related features. GOLD 2026 pocket guide
5. Oxygen and advanced therapies
- Long-term home oxygen improves survival only for people with documented severe chronic resting hypoxemia. It is not routinely prescribed for breathlessness alone.
- Selected people with emphysema may benefit from lung-volume-reduction procedures, endobronchial valves, or lung transplantation after specialist assessment.
- Palliative measures, including treatment of refractory breathlessness and advance-care planning, are appropriate in advanced disease.
Seek urgent medical care now if
Severe breathlessness at rest, blue lips, new confusion/drowsiness, chest pain, inability to speak full sentences, oxygen levels much lower than usual, or failure to improve with rescue inhalers occurs.
This is a shared conversation. Sign in to Orris to start your own chat.